Aprea Therapeutics (APRE) AI Stock Analysis

• Market Cap: $13.32M
• Dividend Yield: N/A
• Average Volume (3M): 30.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.36
• Revenue Growth: 130.31%
• EPS Growth: 86.90%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -2.81
• Shares Outstanding: 5,434,903
• 10 Day Avg. Volume: 22,943
• 30 Day Avg. Volume: 30,194
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 10.03
• Price to Cash Flow (P/CF): -1.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $20.00
• Price Target Upside: 740.34% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Aprea Therapeutics' stock score reflects a mix of potential and risk. The company's strong balance sheet with no debt provides financial stability, but ongoing net losses and negative cash flow highlight profitability concerns. Technical indicators suggest moderate bullish momentum, yet the negative P/E ratio indicates valuation challenges. Investors should consider the company's efforts to improve profitability to enhance its position in the biotechnology sector.

Positive Factors

Clinical Trials

No hematologic toxicity has been observed in the ACESOT-1051 Phase 1 clinical trial evaluating APR-1051 in advanced solid tumors.

Safety Profile

The safety profile for ATRN-119 continues to be favorable, which is a departure from other ATRi drugs in development that faced toxicity issues.

Negative Factors

Financial Performance

Aprea announced 3Q24 results, posting EPS of ($0.64) compared with analyst estimate of ($0.62) and consensus of ($0.74).

Aprea Therapeutics Business Overview & Revenue Model

Company Description

Aprea Therapeutics (APRE) is a biotechnology company focused on developing and commercializing novel cancer therapeutics. The company is primarily engaged in the research and development of small-molecule therapeutics that reactivate the tumor suppressor protein p53, aiming to provide innovative treatment options for cancer patients. Aprea's lead product candidate, eprenetapopt, is being investigated for its potential to treat various types of cancers, including hematologic malignancies and solid tumors.

How the Company Makes Money

Aprea Therapeutics Financial Statement Overview

Summary

Aprea Therapeutics shows potential in revenue growth, but profitability remains a significant challenge due to persistent net losses. Its balance sheet is strong with no debt and a high equity ratio, providing financial stability. However, cash flows are still negative, reflecting ongoing operational challenges. The company needs to address its profitability to strengthen its financial position in the biotechnology industry.

Income Statement

Aprea Therapeutics has shown a modest increase in revenue from $583,231 in 2023 to $956,218 in the TTM (Trailing-Twelve-Months). However, the company's net profit margin is negative due to consistent net losses, with a net income of -$13.5 million in the TTM. The gross profit margin is high at approximately 98.3%, indicating effective cost control on the revenue generated, yet the substantial operating losses overshadow this strength.

Balance Sheet

Aprea Therapeutics maintains a strong balance sheet with no debt, resulting in a favorable debt-to-equity ratio of 0. The equity ratio stands at 81.6%, indicating a strong equity position relative to total assets. However, the return on equity is negative due to net losses, which is a concern for profitability.

Cash Flow

The company has improved its operating cash flow slightly from -$12.1 million in 2023 to -$13.8 million in the TTM, though still negative. Free cash flow has improved from -$12.3 million to -$6.4 million, showing progress in cash management. The operating cash flow to net income ratio is close to 1, indicating alignment between cash flow and reported earnings, but overall cash flow remains negative.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
956.22K	583.23K	0.00	0.00	0.00	0.00
	Gross Profit
939.77K	576.18K	-186.44K	-271.68K	-229.61K	-170.25K
	EBIT
-14.77M	-15.47M	38.18M	-38.04M	-52.15M	-31.04M
	EBITDA
-14.52M	-14.28M	-112.48M	-36.86M	-53.25M	-27.89M
	Net Income Common Stockholders
-13.51M	-14.29M	-224.88M	-36.54M	-53.92M	-26.41M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
65.68M	21.61M	28.79M	53.08M	89.02M	130.09M
	Total Assets
66.02M	22.65M	30.16M	56.82M	92.81M	133.61M
	Total Debt
0.00	0.00	0.00	190.47K	335.16K	544.95K
	Net Debt
-65.68M	-21.61M	-28.79M	-52.89M	-88.68M	-129.54M
	Total Liabilities
117.46M	5.70M	4.51M	7.32M	15.41M	9.36M
	Stockholders Equity
-51.44M	18.26M	25.64M	49.51M	77.40M	124.24M
Cash Flow		Free Cash Flow
-6.41M	-12.27M	-25.01M	-37.69M	-41.83M	-26.74M
	Operating Cash Flow
-13.81M	-12.18M	-25.01M	-37.69M	-41.80M	-26.71M
	Investing Cash Flow
―	-93.09K	0.00	0.00	-25.71K	-30.90K
	Financing Cash Flow
14.58M	5.14M	682.97K	1.75M	150.95K	92.58M

Aprea Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APRE, the sentiment is Negative. The current price of 2.38 is below the 20-day moving average (MA) of 2.68, below the 50-day MA of 3.35, and below the 200-day MA of 3.53, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 36.96 is Neutral, neither overbought nor oversold. The STOCH value of 35.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APRE.

Aprea Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZLAB	59 Neutral	$3.88B	―	-31.41%	―	49.59%	24.92%
REPL	53 Neutral	$932.65M	―	-50.50%	―	―	4.28%
APRE	51 Neutral	$13.32M	―	-60.22%	―	130.31%	86.90%
Sector *	49 Neutral	$6.84B	0.05	-53.14%	2.48%	24.49%	-3.26%
KURA	45 Neutral	$591.93M	―	-42.91%	―	―	2.90%
CYCN	45 Neutral	$6.91M	―	-30.36%	―	―	86.52%
PMVP	39 Underperform	$65.44M	―	-29.23%	―	―	21.33%

Aprea Therapeutics Corporate Events

Aprea Therapeutics Reports Promising Results for APR-1051 Trials

Aprea Therapeutics has announced promising preliminary safety results for its WEE1 inhibitor, APR-1051, showcased at an international oncology conference. The Phase 1 trial indicates APR-1051 is safe and well-tolerated without serious side effects, presenting potential as a treatment for advanced solid tumors. With ongoing trials in the U.S., the company is optimistic about further exploring APR-1051’s therapeutic potential, aiming for more efficacy data in 2025.